Editas Medicine Future Growth

Future criteria checks 0/6

Editas Medicine is forecast to grow earnings and revenue by 7.7% and 0.7% per annum respectively. EPS is expected to grow by 19.5% per annum. Return on equity is forecast to be -225.9% in 3 years.

Key information

7.7%

Earnings growth rate

19.5%

EPS growth rate

Biotechs earnings growth	42.3%
Revenue growth rate	0.7%
Future return on equity	-225.9%
Analyst coverage	Good
Last updated	16 Dec 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:8EM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	10	-164	-154	-154	11
12/31/2025	21	-145	-179	-159	17
12/31/2024	43	-228	-140	-128	17
9/30/2024	62	-211	-191	-182	N/A
6/30/2024	67	-193	-172	-165	N/A
3/31/2024	69	-166	-151	-146	N/A
12/31/2023	78	-153	-137	-132	N/A
9/30/2023	25	-195	-156	-152	N/A
6/30/2023	19	-206	-169	-165	N/A
3/31/2023	23	-219	-168	-164	N/A
12/31/2022	20	-220	-181	-177	N/A
9/30/2022	26	-201	-176	-170	N/A
6/30/2022	32	-184	-171	-162	N/A
3/31/2022	26	-186	-174	-164	N/A
12/31/2021	26	-193	-172	-164	N/A
9/30/2021	24	-214	-176	-169	N/A
6/30/2021	81	-167	-189	-183	N/A
3/31/2021	92	-135	-180	-175	N/A
12/31/2020	91	-116	-187	-180	N/A
9/30/2020	92	-91	-106	-99	N/A
6/30/2020	33	-132	-79	-71	N/A
3/31/2020	24	-142	-73	-66	N/A
12/31/2019	21	-134	-47	-41	N/A
9/30/2019	14	-121	-86	-80	N/A
6/30/2019	25	-103	-66	-61	N/A
3/31/2019	30	-108	-57	-52	N/A
12/31/2018	32	-110	-50	-46	N/A
9/30/2018	29	-121	-76	-72	N/A
6/30/2018	21	-132	N/A	-92	N/A
3/31/2018	17	-120	N/A	-102	N/A
12/31/2017	14	-120	N/A	-9	N/A
9/30/2017	11	-124	N/A	2	N/A
6/30/2017	6	-118	N/A	13	N/A
3/31/2017	6	-111	N/A	29	N/A
12/31/2016	6	-97	N/A	-50	N/A
9/30/2016	6	-71	N/A	-45	N/A
6/30/2016	6	-57	N/A	-39	N/A
3/31/2016	2	-86	N/A	-9	N/A
12/31/2015	2	-73	N/A	-5	N/A
9/30/2015	1	-66	N/A	-1	N/A
6/30/2015	0	-62	N/A	9	N/A
3/31/2015	N/A	-17	N/A	-13	N/A
12/31/2014	N/A	-14	N/A	-9	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8EM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8EM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8EM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8EM's revenue (0.7% per year) is forecast to grow slower than the German market (5.7% per year).

High Growth Revenue: 8EM's revenue (0.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 8EM is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 03:57
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Editas Medicine, Inc. is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
Joel Beatty	Baird
Huidong Wang	Barclays

Editas Medicine Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Editas Medicine, Inc. to Eliminate Approximately 65% of its Workforce over the Next Six Months

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$0.55 loss in 3Q 2023)

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

Executive VP & Chief Scientific Officer recently sold €59k worth of stock

New major risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold €62k worth of stock

CFO & Executive VP recently sold €115k worth of stock

Independent Lead Director recently bought €235k worth of stock

First quarter 2024 earnings released: US$0.76 loss per share (vs US$0.71 loss in 1Q 2023)

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold €674k worth of stock

Full year 2023 earnings released: US$2.02 loss per share (vs US$3.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.81 loss in 3Q 2022)

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.78 loss in 2Q 2022)

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Insider selling

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Insider recently sold €58k worth of stock

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.74 loss in 1Q 2022)

Full year 2022 earnings released: US$3.21 loss per share (vs US$2.85 loss in FY 2021)

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Third quarter 2022 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2021)

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$0.81 loss in 2Q 2021)

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

First quarter 2022 earnings released: US$0.74 loss per share (vs US$0.86 loss in 1Q 2021)

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Editas Medicine, Inc. Terminates Lisa Michaels as Chief Medical Officer

Chairman recently sold €436k worth of stock

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Editas Medicine, Inc. Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

Executive VP & Chief Medical Officer recently sold €52k worth of stock

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.13 profit in 3Q 2020)

Chairman recently sold €452k worth of stock

Editas Medicine, Inc. Announces Initial Clinical Data from Clinical Trial of EDIT-101 for an Oral Presentation at the XIXth International Symposium on Retinal Degeneration

Editas Medicine, Inc. Presents Data on New Sleek Gene Editing Technology

Second quarter 2021 earnings released: US$0.81 loss per share (vs US$0.43 loss in 2Q 2020)

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the Brilliance Clinical Trial of Edit-101 for the Treatment of Lca10 Following Idmc Endorsement

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

First quarter 2021 earnings released: US$0.86 loss per share (vs US$0.69 loss in 1Q 2020)

Chairman recently bought €958k worth of stock

Full year 2020 earnings released: US$1.98 loss per share (vs US$2.68 loss in FY 2019)

Revenue beats expectations

Editas Medicine Announces Update on Clinical Updates

Editas Medicine, Inc. Appoints James C. Mullen as President

President recently sold €70k worth of stock

Editas Medicine, Inc. Announces Management Changes, Effective February 15, 2021

CFO, Principal Accounting Officer recently sold €101k worth of stock

Editas Medicine, Inc. Announces Steps Down of Charles Albright as Chief Scientific Officer, Effective January 15

Editas Medicine, Inc. Names Meeta Chatterjee, Ph.D., to Board of Directors

Editas Medicine Announces Submission of Investigational New Drug Application for EDIT-301 with the U.S. Food and Drug Administration

New 90-day high: €33.20